Database lists somatic EGFR mutations

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

GENEVA-A free online database brings together data on all of the known somatic mutations in EGFR, coupled with data on the response of NSCLCs treated with tyrosine kinase inhibitors, Samuel Murray, PhD, of Metropolitan Hospital, Athens, Greece, reported at the 1st European Lung Cancer Conference (abstract 750).

GENEVA-A free online database brings together data on all of the known somatic mutations in EGFR, coupled with data on the response of NSCLCs treated with tyrosine kinase inhibitors, Samuel Murray, PhD, of Metropolitan Hospital, Athens, Greece, reported at the 1st European Lung Cancer Conference (abstract 750). A literature search identified 202 eligible peer-reviewed articles on somatic mutations in EGFR pertaining to NSCLC. Of 12,244 screened NSCLC patients, 3,381 had EGFR mutations, including 254 different mutations. The database, which is updated every 6 months, is available at www.EGFR-mutations.org.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content